undamentalytics Newsletter
Sign in

Starling Oncology, Inc. balance sheet

At the end of fiscal 2025, Starling Oncology, Inc. had total assets of $165m, total liabilities of $180m and shareholders' equity of −$15.7m. It held $33.6m in cash against $85.9m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents11151433503441
Receivables17204042485966
Inventory46914101720
Total current assets30154130143112113129
Goodwill1427217777
Total assets66203262209173165178
Accounts payable1316914244360
Deferred revenue (current)—01122—
Total current liabilities29303035527195
Short-term debt500————
Long-term debt708187937780
Total debt1201101101108686
Total liabilities3899138152169180203
Shareholders' equity28104123574−16−25
Shares outstanding58m73m73m74m76m99m100m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CDNA vs STLNSTLN vs USPHCRVL vs STLN

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Starling Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Starling Oncology, Inc.